GlassScriptPhysician profile
Andrew Albert Huttenhoff
NPI 1992718662
$1,267.24
in general payments reported to CMS, 2019-2025
20 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
See the full distribution for Corneal and Contact Management
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.30 · 2020: $86.48 · 2021: $286 · 2022: $203 · 2023: $209 · 2024: $266 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $620 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $619.79 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $204.07 | 2022-2024 | Infuse, Vyzulta, Miebo |
| Novartis Pharmaceuticals Corporation | $195.93 | 2020-2022 | |
| Abbvie INC. | $172.78 | 2023-2025 | |
| Eyevance Pharmaceuticals LLC | $82.94 | 2021-2022 | |
| Oyster Point Pharma, INC. | $62.20 | 2022-2024 | Ryzumvi, Tyrvaya |
| Kala Pharmaceuticals, INC. | $62.13 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $57.35 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $56.52 | 2019-2021 | |
| Amgen INC. | $51.03 | 2024-2025 | Tepezza |
| Allergan, INC. | $45.34 | 2020-2022 | |
| Horizon Therapeutics Plc | $41.30 | 2021-2023 | Tepezza |
| Alcon Vision LLC | $37.11 | 2022-2025 | Tryptyr |
| Tarsus Pharmaceuticals, INC. | $36.15 | 2024 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $31.90 | 2025 | |
| Harrow Eye, LLC | $26.79 | 2025 | Vevye |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $23.98 | 2022 | |
| Merz Pharmaceuticals, LLC | $22.43 | 2025 | Xeomin |
| Biotissue Holdings INC. | $22.34 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $19.23 | 2023 | Tecnis Iol |
| Dompe US, INC. | $15.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Huttenhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.